NEW YORK, September 18, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Boston Scientific Corporation (NYSE: BSX),
Abbott Laboratories (NYSE: ABT), Medtronic PLC (NYSE: MDT), Stryker
Corporation (NYSE: SYK), and Edwards Lifesciences Corporation
(NYSE: EW). Free research report on Boston Scientific can be
accessed at https://www.erionline.net/reports?keyword=BSX On
Thursday, September 17, 2015, the
NASDAQ Composite ended at 4,893.95, up 0.10%, the Dow Jones
Industrial Average edged 0.39% lower, to finish the day at
16,674.74, and the S&P 500 closed at 1,990.20, down 0.26%. The
losses were broad based as five out of nine sectors ended the
session in negative. Register for your complimentary reports at the
links given below.
On Thursday, shares in Boston Scientific Corp. recorded a
trading volume of 8.41 million shares, close to their three months
average volume of 8.40 million shares. The stock ended the day
0.53% higher at $17.20. Boston
Scientific Corp.'s stock has fallen by 2.05% in the last one month
and 4.55% in the previous three months. However, the stock has
surged 29.81% on YTD basis. The company is trading above its 50-day
and 200-day moving averages by 0.25% and 4.09%, respectively.
Furthermore, shares of Boston Scientific Corp. have a Relative
Strength Index (RSI) of 54.01. Sign up and read the free notes on
BSX at:
https://www.erionline.net/reports?keyword=BSX
Abbott Laboratories' stock edged 0.87% higher, to close
Thursday's session at $44.24. The
stock recorded a trading volume of 7.19 million shares, above its
three months average volume of 5.99 million shares. Over the last
one month and the previous three months, Abbott Laboratories'
shares have lost 12.29% and 10.99%, respectively. Additionally, the
stock has edged 0.23% lower since the start of this year. The
company is trading 7.85% and 5.44% below its 50-day and 200-day
moving averages, respectively. Furthermore, Abbott Laboratories'
stock traded at a PE ratio of 28.00 and has an RSI of 42.63. The
complimentary notes on ABT can be downloaded in PDF format at:
https://www.erionline.net/reports?keyword=ABT
Medtronic PLC's stock finished Thursday's session 0.98% higher
at $70.81. A total of 5.97 million
shares were traded, which was above its three months average volume
of 5.71 million shares. Over the last one month and the previous
three months, Medtronic PLC's shares have lost 9.32% and 7.24%,
respectively. Additionally, the stock has declined 1.04% since the
beginning of 2015. The company's shares are trading below their
50-day and 200-day moving averages by 5.21% and 5.62%,
respectively. Medtronic PLC's stock traded at a PE ratio of 29.63
and has an RSI of 44.96. Register for free on Equity Research
Institute and access the latest research on MDT at:
https://www.erionline.net/reports?keyword=MDT
On Thursday, shares in Stryker Corp. ended the session 0.04%
lower at $100.56. The stock reported
a trading volume of 1.67 million shares, above its three months
average volume of 1.30 million shares. Shares of the company traded
at a PE ratio of 41.21. Although, Stryker Corp.'s shares have
declined 3.60% in the last one month, it has advanced 3.88% in the
previous three months and 7.39% on YTD basis. The company is
trading 0.89% above its 50-day moving average and 5.82% above its
200-day moving average. Moreover, shares of Stryker Corp. have an
RSI of 54.24. The complete research on SYK is available for free
at:
https://www.erionline.net/reports?keyword=SYK
Edwards Lifesciences Corp.'s stock edged 0.73% higher, to close
the day at $141.61. The stock
recorded a trading volume of 0.65 million shares, below its three
months average volume of 1.09 million shares. Over the last one
month and over the past three months, Edwards Lifesciences Corp.'s
shares have fallen by 2.52% and 2.41%, respectively. However, the
stock has advanced 11.17% since the start of this year. The
company's shares are trading 3.09% above their 200-day moving
average. Additionally, Edwards Lifesciences Corp. traded at a PE
ratio of 35.31 and has an RSI of 49.06. Free in-depth research on
EW is available at:
https://www.erionline.net/reports?keyword=EW
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the Sponsor (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.erionline.net.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) erionline.net.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.erionline.net